MDA 19 had an IC50 for cell viability of 36.3 μM in M14 cells after 24 h of incubation. In Hep3B cells incubated for 48 h, the IC50 for cell proliferation was 56.69 μM. In U2OS cells treated for 72 h, concentrations higher than 20 µM produced cell viability lower than 50% compared with 0 µM. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Cell viability in M14 cells
Cell-based study · M14 cells [1]
M14 cells were incubated with MDA 19 for 24 h. The IC50 for cell viability was 36.3 μM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 1, 2, 4, 6, 8, 10, 20, 40, 60, 80, 100, and 200 μM
- Exposure duration
- 24 h of incubation
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: MDA 19
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Dose-dependent assay (S2, S3); Results > MDA-19 inhibits melanoma cells in a dose-dependent manner (S34, S36)
viability of M14 cells: viability of M14 cells; comparator: 0 μM — Results > MDA-19 inhibits melanoma cells in a dose-dependent manner (S34, S36)
Cell proliferation in Hep3B cells
Cell-based study · Hep3B [2]
Hep3B cells were incubated with the compound for 48 h. The cell proliferation IC50 was 56.69 μM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 5, 10, 20, 30, 40, 50, 80, 100, and 120 μM
- Exposure duration
- for 48 h
- Method
- incubate with HCC cells
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: MDA 19
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Cells culture and treatment (S2); Methods > Dose-dependent assay (S17, S18); Results > MDA19 inhibited proliferation of HCC cells in a dose- and time-dependent manner (S51)
Cell proliferation: Cell proliferation; comparator: 0 μM — Methods > Dose-dependent assay (S18); Results > MDA19 inhibited proliferation of HCC cells in a dose- and time-dependent manner (S51)
Viability response in U2OS cells
Cell-based study · U2OS [3]
U2OS cells were treated with MDA 19 for 72 h. At concentrations higher than 20 µM, cell viability was lower than 50% compared with that at 0 µM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 1, 2.5, 5, 10, 20, 50, 100, 200 µM
- Exposure duration
- 72 h
- Method
- cells were administrated with MDA19
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: MDA 19
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Cell proliferation assay (S16, S17); Results > Effect of MDA19 on proliferation of OS cells (S45, S46)
cells’ viability by measuring OD value: cells’ viability by measuring OD value; comparator: 0 µM — Results > Effect of MDA19 on proliferation of OS cells (S45, S46)